Patents Assigned to Grunenthal GmbH
  • Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
    Patent number: 9775843
    Abstract: The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: October 3, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Petra Bloms-Funke, Gregor Bahrenberg, Wolfgang Schröder, Sven Kühnert, Simon Lucas
  • Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
    Publication number: 20170273970
    Abstract: The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.
    Type: Application
    Filed: June 14, 2017
    Publication date: September 28, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: Petra BLOMS-FUNKE, Gregor Bahrenberg, Wolfgang Schröder, Sven Kühnert, Simon Lucas
  • Pharmaceutical dosage form
    Patent number: 9750701
    Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 5, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Eugeen Marie Jozef Jans, Filip René Irena Kiekens, Jody Firmin Marceline Voorspoels, Anne Faure, Iris Ziegler, Elisabeth Arkenau-Maric, Lutz Barnscheid, Johannes Bartholomäus, Marc Frevel, Eric Galia, Andrea Schüessele
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20170239185
    Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMAEUS, HEINRICH KUGELMANN
  • Tamper resistant dosage form with bimodal release profile
    Patent number: 9737490
    Abstract: The invention relates to a pharmaceutical dosage form comprising (i) at least one formed segment (S1), which contains a first pharmacologically active ingredient (A1) and provides prolonged release thereof, and (ii) at least one further segment (S2), which contains a second pharmacologically active ingredient (A2) and provides immediate release thereof, wherein the at least one formed segment (S1) exhibits a higher breaking strength than the at least one further segment (S2) and the at least one formed segment (S1) exhibits a breaking strength of more than 500 N.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: August 22, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Lutz Barnscheid, Anja Geiβler, Klaus Wening, Stefanie Strauch, Jana Pätz, Sebastian Schwier
  • 3-oxo-tetrahydro-furo[3,2-B]pyrrol-4(5H)-yl) derivatives I
    Patent number: 9725459
    Abstract: The invention relates to amidic oxotetrahydro-2H-furo[3.2-b]pyrrol-4(5H)-yl) derivatives as dual CatS/K inhibitors. to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: August 8, 2017
    Assignee: GRUNENTHAL GMBH
    Inventors: Antonio Nardi, Paul Ratcliffe, Tobias Craan, Torsten Hertrampf, Bernhard Lesch, Robert Kime, Henning Steinhagen
  • ABUSE-PROOFED ORAL DOSAGE FORM
    Publication number: 20170209378
    Abstract: The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: March 1, 2016
    Publication date: July 27, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20170209379
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Application
    Filed: March 15, 2017
    Publication date: July 27, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU-MARIC, Johannes BARTHOLOMAEUS, Heinrich KUGELMANN
  • Substituted condensed pyrimidine compounds
    Patent number: 9688683
    Abstract: Novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 27, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Florian Jakob, Ingo Konetzki, Tobias Craan, Antonio Nardi, Christian Hesslinger
  • Oral forms of a phosphonic acid derivative
    Patent number: 9682091
    Abstract: Novel solution complexes of zoledronic acid are described which give rise to improved properties of zoledronic acid. The invention includes aqueous solution and molecular complexes of zoledronic acid with and optical isomers of asparagine, histidine, arginine and proline as well as pharmaceutical complexes containing them and methods of treatment using them.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: June 20, 2017
    Assignee: GRUNENTHAL GMBH
    Inventors: Mazen Hanna, Ning Shan, Miranda Cheney, David R. Weyna
  • Abuse-proofed dosage form
    Patent number: 9675610
    Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 13, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Johannes Bartholomaeus, Heinrich Kugelmann
  • Substituted condensed pyrimidine compounds
    Patent number: 9670189
    Abstract: The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: June 6, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Ingo Konetzki, Florian Jakob, Tobias Craan, Christian Hesslinger, Paul Ratcliffe, Jason J. Shiers
  • Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
    Patent number: 9655853
    Abstract: The invention relates to a pharmaceutical dosage form having a breaking strength of at least 300 N and comprising a pharmacologically active compound, an anionic polymer bearing carboxylic groups, wherein the content of the anionic polymer is ?20 wt.-%, based on the total weight of the pharmaceutical dosage form, and a nonionic surfactant.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 23, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Lutz Barnscheid, Jessica Redmer, Sebastian Schwier
  • PHARMACEUTICAL SALTS
    Publication number: 20170137370
    Abstract: The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments.
    Type: Application
    Filed: February 1, 2017
    Publication date: May 18, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: JOHANNES BARTHOLOMÄUS, HEINRICH KUGELMAN
  • HETEROARYL SUBSTITUTED HETEROCYCLYL SULFONES
    Publication number: 20170121314
    Abstract: The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Application
    Filed: January 12, 2017
    Publication date: May 4, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: STEFAN SCHUNK, Melanie Reich, Florian Jakob, Nils Damann, Michael Haurand, Achim Kless, Marc Rogers, Kathy Sutton
  • NOVEL GASTRO-RETENTIVE DOSAGE FORMS
    Publication number: 20170119663
    Abstract: A gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for formulating for once daily or twice daily administration. Further provided is a method of treating a disorder by administering to a patient in need thereof, a gastro-retentive pharmaceutical dosage form of a therapeutically effective amount of at least one GABA Analog, at least one opioid, and at least one pharmaceutically acceptable excipient wherein the said dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. The opioid is either in slow release form or in immediate release form.
    Type: Application
    Filed: December 13, 2016
    Publication date: May 4, 2017
    Applicant: Grünenthal GmbH
    Inventor: Ramesh SESHA
  • TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
    Publication number: 20170112766
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: January 9, 2017
    Publication date: April 27, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, ANJA GEIßLER, JANA DENKER, LUTZ BARNSCHEID
  • Abuse-proofed dosage form
    Patent number: 9629807
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: April 25, 2017
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Maric, Johannes Bartholomaeus, Heinrich Kugelmann
  • PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES
    Publication number: 20170101398
    Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: Stefan SCHUNK, Melanie Reich, René Michael Koenigs
  • PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES
    Publication number: 20170101397
    Abstract: The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Applicant: GRÜNENTHAL GMBH
    Inventors: Stefan Schunk, Melanie Reich, René Michael Koenigs